Cibotercept
Cibotercept (KER-012) is a novel, modified, investigational activin receptor type IIB (ActRIIB) ligand trap designed to target select TGF-β ligands, including activins A and B, GDFs 8 and 11, to rebalance the defective activin receptor type II signaling observed in PAH[1][2].
Product Specifications
CAS Number
2769700-97-0
Product Name Alternative
KER-012
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cibotercept.html
Purity
99.85
References & Citations
[1]Cibotercept|[2]Sebastien J. Sannajust, et al. Nonclinical Assessment of Cibotercept (KER-012), A Novel Modified ActRIIB Ligand Trap, For the Treatment of Pulmonary Arterial Hypertension.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
